StreetAlpha.app
Home › Stocks › EIKN

Eikon Therapeutics, Inc. (EIKN)

Healthcare
$5.15
▼ −4.36%
LAST CLOSE · NOV 17

Eikon Therapeutics develops cancer medicines, with its most advanced candidate in Phase 2/3 trials for melanoma. It last closed at $5.15 on Nov 17, down 4.36% on the day.

AI Auto Pilots
Is EIKN in one of our four AI portfolios? Sign in free to see
Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated EIKN in the past 90 days, not enough for a consensus
Average 12-month target
$23.00
▲ 346.6% upside

Based on 1 analyst who set a price target on EIKN in the past 90 days. The average target is $23.00, with a high of $23.00 and a low of $23.00, compared with the last close of $5.15.

Low $23.00Avg $23.00High $23.00
Blue marker: last close $5.15
Highest target$23.00
Average target$23.00
Lowest target$23.00
Latest rating changes
HC Wainwright & Co.Initiated
Oct 16Buy$23
WedbushMaintained
Aug 14Sell$4
DateFirmActionRatingPrice target
Oct 16HC Wainwright & Co.InitiatedBuy$23
Aug 14WedbushMaintainedSell$4
Loading…

Technical Analysis

EIKN · as of the Nov 17 close · updated after every close
Falling, nearing oversold

The stock is 18% below its 20 day and 42% below its 50 day average. Momentum is fading (RSI 36), near oversold. The nearest support is the swing low (Oct 30) at $5.01, and the nearest resistance the Pivot at $5.16.

Short trendBearish
Long trendNot enough history
MomentumFading
StretchNear oversold
VolatilityNormal, 12.9%/day
Key levels
$17.4052 week high+237.9%
$8.95100 day average+73.8%
$7.3150 day average+41.9%
$6.43Swing high (Nov 5)+24.9%
$6.0720 day average+17.9%
$5.38Pivot R1+4.5%
$5.16Pivot+0.2%
$5.15Last close
$5.01Swing low (Oct 30)−2.7%
$4.9552 week low−3.9%
$4.94Pivot S1−4.1%
Indicators
RSI (14)36.01Weak, oversold below 30Neutral
MACD-0.50Above its signal lineBullish
Stochastic28.5Middle of its rangeNeutral
ADX (14)19.1No clear trend
Williams %R-89.3Oversold below −80, overbought above −20Oversold
CCI (20)-106.2Oversold below −100, overbought above 100Oversold
Rate of change−7.2%Change over 10 sessionsBearish
ATR (14)$0.67Typical daily range, 12.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for EIKN

What happened before

See how EIKN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in EIKN in the last 90 days.

Loading…

See today’s whale options flow across the market →

EIKN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲74 buying vs 18 selling
  • ▲Shares held by funds +19.5%
  • ▲Funds holding +21
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding9877+27.3%
In funds' top 1045−20.0%
Held by funds–––
New / increased30 / 4437 / 17+37.0%
Reduced / sold out9 / 99 / 12−14.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See EIKN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EIKN is in one of them and how their past EIKN trades turned out.

EIKN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered EIKN in an article yet. Here's the latest on the wider market.

About Eikon Therapeutics

Eikon Therapeutics is a biopharmaceutical company based in Millbrae, California, that is developing medicines for cancer. Its main focus is oncology, and its most advanced candidate, EIK1001, is in Phase 2/3 trials with pembrolizumab for advanced melanoma. The company also has candidates that inhibit PARP1 for ovarian, breast, prostate and pancreatic cancers, plus an early-stage helicase inhibitor. Its medicines are still in clinical development and are not yet sold to patients.

Headquarters
Millbrae, CA